Gleneagle Gold (ASX:GLN) has positioned itself at the forefront of the medical cannabis sector, after entering into an agreement to acquire 100% of the issued capital of Zelda Therapeutics Pty Ltd.
Zelda has now appointed medical clinician, Dr Joe Goldstrich, to the company’s Scientific Advisory Board, with immediate effect.
Dr Goldstrich holds over 40 years of clinical medicine experience, including caring for and evaluating thousands of patients receiving medicinal cannabis.
His knowledge and experience in the US medical cannabis industry will be instrumental in shaping Zelda’s rigorous scientific research and clinical trials.
Harry Karelis, Zelda chairman, commented:
"We are honoured to have a clinician of Dr Goldstrich's calibre and experience joining the Zelda team.
"With a medical career spanning over 40 years and his evidence-based evaluations of the benefits that thousands of patients receive from medical cannabis treatments, his guidance will be instrumental in helping to place Zelda at the forefront of cannabis-based medicines."
Dr Joe Goldstrich, added:
“Whilst the medical cannabis industry is well established in the US and Europe, the medicine is still wildly under-researched.
"It is for this reason I am delighted to join the Scientific Advisory Board of Zelda Therapeutics as they look to validate the use of medical cannabis in treating a variety of ailments and serious illnesses through extensive scientific research and clinical trials.”
Other members of the Scientific Advisory Board include
Professor Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.
Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain and specialist in the area of lipid signaling, including cannabinoids in an oncology setting.
Dr Donald Abrams: A cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion and Chief of Haematology and Oncology at San Francisco General Hospital.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.